Review examines sex-hormone signaling effects on non-reproductive cancers, suggesting new biological insights.
Sex differences in the incidence and outcomes of non-reproductive cancers persist across many tumor types, even after adjustment for major exposure- and care-related factors. This review examines how sex-hormone signaling may contribute to these patterns through tumor-intrinsic mechanisms and regulation of the tumor microenvironment. In tumor cells, ER, AR and PR mediate classical nuclear transcriptional programs, whereas membrane-associated or cytoplasmic receptor pools, together with GPER, support rapid non-genomic signaling through PI3K/AKT, MAPK/ERK and related kinase or second-messenger pathways. Intratumoral steroid handling can create local ligand conditions that differ from circulating hormone levels and modify context-specific receptor activity. Hormonal context may also influence vascular, stromal and immune phenotypes. Clinically, sex-hormone-related tumor states may be better captured by integrated activity-based readouts, including receptor status, pathway activation, local steroid availability and immune context, rather than receptor immunostaining alone. Overall, sex-hormone signaling offers a hypothesis-generating framework for understanding sex-biased tumor biology beyond traditional hormone-driven cancers, but its clinical relevance requires further mechanistic and prospective validation.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: